Cargill’s EpiCor postbiotic ingredient health claims licensed by Health Canada

Photo © AdobeStock.com/elenabsl

Cargill (Minneapolis) announced that Health Canada has licensed 10 health claims for the company’s EpiCor postbiotic ingredient as a Natural Health Product. The health claims focus on support for immune and digestive health.

The claims are based on a daily EpiCor dose of 500 mg in adults aged 18 and older and are backed by more than a dozen published clinical studies, the company says. The claims include:

• Helps to reduce the incidence of cold and flu symptoms (during the winter months)
• Helps to reduce the symptoms of seasonal allergies such as nasal stuffiness/congestion
• Helps relieve nasal stuffiness/congestion associated with seasonal allergies
• Helps to maintain immune function
• An antioxidant that helps to support good health
• Source of antioxidant(s)/provides antioxidant(s)
• Helps support intestinal/gastrointestinal health
• Helps to improve occasional mild to moderate bloating/distension
• Helps to improve occasional mild to moderate feeling of fullness
• Occasionally helps to improve stool consistency

In a press release, Justin Green, PhD, director of scientific affairs for EpiCor, added, “This news, from one of the world’s leading health agencies, affirms the significant body of science behind EpiCor…”